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Legionellosis is an acute pneumonia that can be fatal particularly in undetectable level, yet few days of ﬂuoroquinolone treatmentwere suf-
immunocompromised patients, if not treated promptly. The pre-
eminent causative agent, Legionella pneumophila, like other Legionella
species, is an inhabitant of aquatic biotopes and ofman-madewater sys-
tems, including also home drinking water sources, where it can survive
and replicate intracellularly in free-living amoebae and protozoa
(Pedro-Botet et al., 2002; Taylor et al., 2009). Occasionally, humans
can be infected by inhaling contaminated aerosols, with Legionella
reaching the alveoli of the lungs, where it is engulfed by macrophages.
In contrast to most bacteria which are destroyed there, Legionella can
proliferate inside a Legionella-containing-vacuole, similarly to what oc-
curs in amoebae, eventually killing the macrophage and giving rise to
the disease (Isberg et al., 2009). Antibiotic therapy with macrolides or
ﬂuoroquinolones is the ﬁrst choice in legionellosis and is usually effec-
tive in killing the bacteria and curing most patients, though treatment
failure or relapses may occur (Roig and Rello, 2003).
Human to human transmission has not been reported for
L. pneumophila, and the bacteria that proliferate in legionellosis patients
will disappear or die with the patient. Chances for them to reach the nat-
ural environment are negligible. For this reason, the development of anti-
biotic resistance in patients with persisting or relapsing Legionella
infections has not been considered an issue, though it is well known
that the same antibiotics used in the clinic will select for mutants in in-
vitro experiments (Roig and Rello, 2003).
The results obtained by Lubana Shadoud and colleagues (Shadoud
et al., 2015) cast now some doubts on this conclusion, as they show
the emergence ofﬂuoroquinolone resistance in vivo in twopatients hos-
pitalized for Legionella infection. By taking advantage of the characteri-
zation of the genetic locus for quinolone resistance and its mutational
pathway (Almahmoud et al., 2009), the authors have devised and stan-
dardized a speciﬁc qPCR assay to detect ﬂuoroquinolone resistancemu-
tations. The assay was applied to lower respiratory samples of 82
legionellosis patients, four of which displayedmutations that were con-
ﬁrmed by next generation sequencing. More important, in two patients
it could be shown that the mutated forms were progressively replacing
the wild-type DNA during the antibiotic treatment, suggesting in vivo
selection of ﬂuoroquinolone resistant mutants. It is worth mentioning
that only few mutations in a small region of the quinolone resistance
locus could be analyzed, leading the authors to conclude that the inci-
dence of in vivo selection of ﬂuoroquinolone resistance might be much
higher. Did the mutations arise during the antibiotic treatment? It is
more likely that both patients were already infected with a heteroge-
neous Legionella population containing the resistant alleles at almostDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.07.018.
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These ﬁndings are important because they show that selection for
ﬂuoroquinolone resistance may be induced by the antibiotic treatment,
withworsening of the disease, as it was the case for the two patients, al-
though it could be objected that two cases are statistically not signiﬁ-
cant. Decades ago in a similar study, but with totally different assay,
no resistant mutants were isolated in 98 clinical samples (Onody et al.,
1997). On the other hand, an independent case of ﬂuoroquinolone-
resistant L. pneumophila isolated from a clinical specimen was reported
recently (Bruin et al., 2014). Thus, taken together these results sound as
an alarm-bell that lack of clinical response during treatment with quin-
olone could be due to selection of resistant mutants of L. pneumophila,
and this should be taken in consideration for a more appropriate treat-
ment. The results also justify the practice of combined antibiotic treat-
ment with macrolide and quinolone in severe Legionella cases. Further
systematic investigations, not only for Legionnaire's disease but also
for other infectious diseases caused by pathogens with strict intracellu-
lar lifestyles, are needed in order to shed more light on the incidence of
antibiotic resistance during antibiotic therapy.
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